Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Sleepman who wrote (30161)	1/12/2000 12:51:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Dan, Targretin is a rexinoid, which means it preferentially binds RXRs over RARs. The retinoids in the literature prefer RARs over RXRs. There may be some metabolites however that blur the distinction in vivo. I believe that there were some interferon combination trials (kidney?) that I think was with Targretin, but may have been with Panretin (Panretin, as its name implies activates RARs and RXRs. However, there hasn't been much news on that front, so I suspect that the data was less impressive than LGND's current targets, which as far as in house drugs are concerned, seems centered on Targretin and ONTAK, both of which have shown promising clinical results on diseases whose incidence is much larger than CTCL.